The Chemours Company (NYSE:CC) is Luminus Management LLC's 4th Largest Position

Luminus Management LLC decreased its holdings in shares of The Chemours Company (NYSE:CC - Free Report) by 62.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 601,541 shares of the specialty chemicals company's stock after selling 1,014,661 shares during the period. Chemours accounts for about 11.7% of Luminus Management LLC's portfolio, making the stock its 4th largest position. Luminus Management LLC owned 0.40% of Chemours worth $10,166,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Barclays PLC boosted its position in Chemours by 28.4% during the third quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company's stock valued at $2,185,000 after purchasing an additional 23,766 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 765 shares during the last quarter. Matrix Trust Co lifted its position in shares of Chemours by 715.7% during the fourth quarter. Matrix Trust Co now owns 9,952 shares of the specialty chemicals company's stock valued at $168,000 after buying an additional 8,732 shares during the last quarter. Inspire Investing LLC boosted its holdings in shares of Chemours by 17.4% in the 4th quarter. Inspire Investing LLC now owns 23,799 shares of the specialty chemicals company's stock valued at $402,000 after buying an additional 3,523 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after buying an additional 1,708 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Stock Performance

Shares of NYSE CC traded down $0.33 during mid-day trading on Thursday, hitting $11.09. The stock had a trading volume of 3,856,085 shares, compared to its average volume of 2,012,797. The company has a 50 day moving average of $12.41 and a two-hundred day moving average of $16.40. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The firm has a market cap of $1.66 billion, a PE ratio of 19.46 and a beta of 1.76. The Chemours Company has a twelve month low of $9.33 and a twelve month high of $29.18.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company's revenue for the quarter was up .4% on a year-over-year basis. During the same period last year, the business earned $0.32 EPS. Research analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 9.02%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's dividend payout ratio is presently 175.00%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Mizuho set a $15.00 target price on shares of Chemours in a research report on Tuesday, April 15th. The Goldman Sachs Group decreased their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday. UBS Group lowered their price objective on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Truist Financial dropped their target price on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, StockNews.com cut Chemours from a "hold" rating to a "sell" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Chemours presently has a consensus rating of "Hold" and an average price target of $17.56.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.